Molecular Studies and Clinical Correlations in Human Prostatic Disease
Prostate Cancer
Conditions: official terms
Prostatic Diseases
Conditions: Keywords
benign, Rising PSA, Clinical Metastases, 90-040
Study Type
Study Phase
Study Design
Observational Model: Case-Only
Overall Status
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.
Detailed Description
The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Male
Criteria: Inclusion Criteria:

Men with prostate conditions representing the following disease states:

- No Cancer Diagnosis

- Clinically Localized Disease

- Rising PSA

- Clinical Metastases: Noncastrate

- Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)

- Signed informed consent

Exclusion Criteria:

-Patients without any prostate related problems.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Susan Slovin, MD - 646-422-4470
Start Date
April 1990
Completion Date
December 2016
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Record processing date processed this data on July 28, 2015 page